Developing and validating serological assays to sars-COV-2 for highly susceptible animal species
Ended Cooperative Agreement Awarded Last action
- Award ID
- U18FD007509
- Recipient
-
Kansas State University UEI CFMMM5JM7HJ9 Part of Kansas State University
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,125,000
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding
-
- $899,999.92 Federal
- $225,000.00 Non-federal
- Funding agency
- Center for Veterinary Medicine Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Kansas, USA
Award details come from USAspending.gov.
Description
- Abstract
- Sars-COV-2 is an enveloped, positive-sense RNA virus that is known to interact with the angiotensin- converting enzyme-2 (ACE2) receptor of several species, including humans, cats, dogs, minks, ferrets, deer, and others. Since its emergence in wuhan, china in late 2019, sars-COV-2, the causative agent of covid- 19, has been classified as a pandemic, causing havoc on public health and resulting in worldwide lockdowns. Due to its sudden emergence, as well as its similarity to sars-COV-1 and mers-COV, IT is suspected that sars-COV-2 likely had an intermediate animal host. However, the similarities in the ACE2 receptors of coronaviruses have sparked the question of which animal species are susceptible to sars-COV-2, and capable of viral transmission. Reverse-zoonosis has been described in a few of these species, indicating that human-animal interactions can pose two-sided risks for sars-COV-2 infection. Therefore, IT is critical to produce accurate diagnostic serological tests for animals to understand prevalence of the virus in the animal population. This project will compare diagnostic results between commercial elisas, developed in-house elisas, and serum neutralization assays for sars-COV-2, as well as western blot against other coronaviruses to rule out cross-reactivity. The outcome of this study will provide insight into the accuracy (SE/SP) of commercially available serological tests, newly developed in-house serological techniques, and collect data on sars-COV-2 prevalence in target species, which will include minks, ferrets, white-tailed deer, domestic dogs and cats, cows, sheep, and goats.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$0 | $0 | |
| Amendment | $225,000 | $0 | |
| Amendment | $225,000 | $0 | |
| Amendment | $225,000 | $0 | |
| Original award | $225,000 | $225,000 |
Quick answers
Who received award U18FD007509?
U18FD007509 was awarded to Kansas State University by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 15, 2021.
How much is award U18FD007509 worth?
$1,125,000 has been obligated on U18FD007509: $900,000 in federal funding and $225,000 in non-federal funding.
Which agency awarded U18FD007509?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U18FD007509, with funding from Center for Veterinary Medicine (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award